Press Releases



 
Press Releases
  Date Title View
Aug 30, 2017
REDWOOD CITY, Calif., Aug. 30, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that it will present at the 2017 Wells Fargo Healthcare Conference in Boston on Wednesday, September 6, 2017 at 9:05 a.m. Eastern Time. To access the live and subsequently archived webcast of the presentation, go to the Investor Relations ...
PDF
Aug 24, 2017
REDWOOD CITY, Calif., Aug. 24, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies, has issued a positive final Local Coverage Determination (LCD) to expand Medicare coverage of the Oncotype DX® Genomic Prostate Sc...
PDF
Aug 1, 2017
REDWOOD CITY, Calif., Aug. 1, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today reported financial results and business progress for the quarter ended June 30, 2017. Total revenue was $85.5 million in the second quarter of 2017, compared with $82.0 million in the second quarter of 2016, an increase of 4 percent, and an increase ...
PDF
Jul 20, 2017
REDWOOD CITY, Calif., July 20, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the company will host a conference call and webcast on Tuesday, August 1 at 4:30 p.m. Eastern Time to discuss its second quarter 2017 financial results. The call and webcast will follow the release of the second quarter financial results aft...
PDF
Jul 12, 2017
REDWOOD CITY, Calif., July 12, 2017 /PRNewswire/ -- Genomic Health, Inc. (NASDAQ: GHDX) today announced that the 15th St. Gallen International Breast Cancer Conference Expert Panel endorsed the use of genomic tests in early-stage breast cancer and recognized the Oncotype DX Breast Recurrence Score® test for its prognostic ability as well as it...
PDF
Jun 2, 2017
REDWOOD CITY, Calif., June 2, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of eight studies that provide additional evidence of the value of Oncotype DX® tests in predicting clinically meaningful endpoints and outcomes across multiple cancer types. The data from patients with invasive breast, ductal...
PDF
May 30, 2017
REDWOOD CITY, Calif., May 30, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will present results from eight Oncotype DX® studies at the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting, which will take place June 2-6 at McCormick Place in Chicago. These presentations represent data ac...
PDF
May 25, 2017
REDWOOD CITY, Calif., May 25, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that it will present at the Jefferies 2017 Healthcare Conference in New York City on Tuesday, June 6, 2017 at 4:30 p.m. Eastern Time. To access the live and subsequently archived webcast of the presentation, go to the Investor Relations sec...
PDF
May 13, 2017
REDWOOD CITY, Calif., May 13, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results from two Oncotype DX® Genomic Prostate Score™ (GPS) test analyses based on a prospective, multi-center, 1,200-patient study. Results of one analysis, presented at the American Urological Association (AUA) 2017 Annual Meeting, pr...
PDF
May 12, 2017
REDWOOD CITY, Calif., May 12, 2017 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced the presentation of new results from a large, community-based, multi-center clinical validation study conducted at Kaiser Permanente, confirming that the Oncotype DX® Genomic Prostate Score™ (GPS) test is a strong independent predictor ...
PDF
FirstPrevious
2
...
NextLast